Literature DB >> 4695622

Light chain proteinuria and humoral immunoincompetence in tuberculous patients treated with rifampin.

C D Graber, J Jebaily, R L Galphin, E Doering.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4695622     DOI: 10.1164/arrd.1973.107.5.713

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


× No keyword cloud information.
  8 in total

Review 1.  Antibiotic agents and the immune mechanisms of defense.

Authors:  J W Alexander
Journal:  Bull N Y Acad Med       Date:  1975-10

2.  Immunosuppressant activity of the ansamycins.

Authors:  J E Kasik; M Monick; J S Thompson
Journal:  Antimicrob Agents Chemother       Date:  1976-03       Impact factor: 5.191

3.  Serologic studies on the occurrence of specific rifampicin antibodies during continuous rifampicin treatment--its frequency and significance.

Authors:  R Kropp; M Krüpe; H Jungbluth
Journal:  Pneumonologie       Date:  1976-04-09

4.  Rifampicin induced light chain proteinuria and renal failure.

Authors:  R J Winter; R A Banks; C M Collins; B I Hoffbrand
Journal:  Thorax       Date:  1984-12       Impact factor: 9.139

5.  Rifampin therapy for Staphylococcus epidermidis endocarditis.

Authors:  P Auger; J P Laaban; G Gagnon; C Meere; I Dyrda; G Marquis; S Montplaisir
Journal:  Can Med Assoc J       Date:  1982-10-01       Impact factor: 8.262

6.  Immunological responsiveness of tuberculosis patients receiving rifampin.

Authors:  F L Ruben; A Winkelstein; I G Fotiadis
Journal:  Antimicrob Agents Chemother       Date:  1974-04       Impact factor: 5.191

7.  Rifampicin-isoniazid induced fatal fulminant hepatitis during treatment of latent tuberculosis: A case report and literature review.

Authors:  Fahmi Yousef Khan; Fatima Rasoul
Journal:  Indian J Crit Care Med       Date:  2010-04

8.  Effect of rifampin on cutaneous hypersensitivity to purified protein derivative in humans.

Authors:  P Mukerjee; S Schuldt; J E Kasik
Journal:  Antimicrob Agents Chemother       Date:  1973-12       Impact factor: 5.191

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.